NCT04580121 2024-06-03A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.Hoffmann-La RochePhase 1 Completed59 enrolled
NCT02923986 2020-05-28Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDSBio-Path Holdings, Inc.Phase 1/2 Withdrawn